➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Moodys
AstraZeneca
Johnson and Johnson
McKinsey

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SANDIMMUNE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sandimmune

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000936 A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Terminated National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1999-11-01 Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
NCT00428064 Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 1998-05-01 To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and sirolimus followed by CsA elimination and concentration-controlled sirolimus.
NCT00520468 Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS Completed M.D. Anderson Cancer Center Phase 2 2004-06-01 Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sandimmune

Condition Name

Condition Name for Sandimmune
Intervention Trials
Myelodysplastic Syndrome 5
Acute Lymphoblastic Leukemia 3
Recurrent Hodgkin Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sandimmune
Intervention Trials
Myelodysplastic Syndromes 8
Syndrome 7
Preleukemia 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sandimmune

Trials by Country

Trials by Country for Sandimmune
Location Trials
United States 13
Czech Republic 1
Austria 1
China 1
South Africa 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sandimmune
Location Trials
Washington 5
New York 3
Texas 2
California 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sandimmune

Clinical Trial Phase

Clinical Trial Phase for Sandimmune
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sandimmune
Clinical Trial Phase Trials
Recruiting 7
Completed 7
Not yet recruiting 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sandimmune

Sponsor Name

Sponsor Name for Sandimmune
Sponsor Trials
National Cancer Institute (NCI) 7
Fred Hutchinson Cancer Research Center 5
M.D. Anderson Cancer Center 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sandimmune
Sponsor Trials
Other 23
NIH 8
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Moodys
Dow
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.